JBJ-04-125-02 cas: 2060610-53-7

CAS NO: 2060610-53-7
MF: C29H26FN5O3S
MW: 543.62
CAS: 2060610-53-7
JBJ-04-125-02
Description Review
Description
Health Advantages

JBJ-04-125-02 is known for its potential to deliver several health advantages,


including:
Accelerated muscle development
Enhanced bone density
Enhanced recuperation periods
Weight reduction
Possible Consequences
Benefits
Increased anabolic activity
Minimized muscle degeneration
Enhanced stamina and power
Enhanced overall physical performance
Adverse Consequences
Possible hormonal imbalances
Prolonged usage may increase the risk of liver damage.
Possibly cardiovascular problems
Product Mechanism
By binding selectively to androgen receptors in muscle and bone tissues, JBJ-04-125-02 exerts its effect. This specific binding increases anabolic activity, which helps muscles grow and bone structure without the bad side effects that come with regular anabolic drugs.

Side Effects and Safety
Risk protection
In general, JBJ-04-125-02 is regarded to be safe when it is taken in a responsible manner and within the doses that are prescribed. Liver function and hormone levels must be monitored to prevent side effects.


Potential Adverse Reactions
Imbalances in hormones
Potential harm to the liver
Cardiovascular problems
Potential inhibition of testosterone production naturally
Information on Dosing
JBJ-04-125-02's normal dose varies from 10 to 30 mg per day, depending on the user's objectives and tolerance. To determine personal reaction and reduce possible side effects, it is best to start at a lower dosage and raise it gradually.

Things that shouldn't be done with JBJ-04-125-02:

Women who are pregnant or breastfeeding
People who have existing liver conditions
Individuals who have a background of cardiovascular diseases
Individuals who are presently taking other drugs that have the potential to interact negatively
In conclusion
JBJ-04-125-02 is a potential SARM for muscle development, bone density, and performance. Even if it's a safer option than anabolic steroids, users still need to be cautious, follow dose instructions, and keep an eye on their health to reduce any hazards. It is strongly suggested that you contact with a healthcare practitioner before beginning usage of any supplement.

People Also Ask
What advantages does JBJ-04-125-02 offer?
JBJ-04-125-02 offers advantages such as greater muscular development, bone density, faster recovery times, and fat reduction.

How does this particular product work?
Anabolic activity is stimulated and muscle growth and bone density enhancements ensue as a consequence of JBJ-04-125-02's selective binding to androgen receptors in bone and muscle tissues.

What are the potential adverse reactions of JBJ-04-125-02?
Hormonal disruptions, liver damage, heart problems, and reduced natural testosterone production are all possible negative reactions to JBJ-04-125-02.

Is JBJ-04-125-02 considered safe?
Using JBJ-04-125-02 responsibly and at authorized doses is safe. It is essential to regularly check hormone levels and liver function in order to prevent negative consequences.

What is the suggested dosage for JBJ-04-125-02?
JBJ-04-125-02 is typically administered at a dose of 10 to 30 mg per day, depending on individual objectives and tolerance. To gauge reaction and reduce possible side effects, it is best to start at a lower dosage and raise it gradually.

Who should steer clear of JBJ-04-125-02?
People who are pregnant or nursing, have liver problems, or have a history of heart disease should not take JBJ-04-125-02. People who are currently taking other medicines that may combine negatively with this drug should also avoid it. 



  • JBJ-04-125-02,
  • BET inhibitor,
  • epigenetic therapy,
  • bromodomain inhibition,
  • cancer treatment,
  • inflammatory disease,
  • transcriptional regulation,
  • BRD4 inhibitor,
  • small molecule inhibitor,
  • gene expression modulation,
  • histone acetylation,
  • chromatin remodeling,
  • therapeutic applications,
  • CAS 2060610-53-7,
  • molecular mechanism of JBJ-04-125-02,
  • epigenetic drug development,
  • novel BET inhibitors,
  • selective bromodomain inhibitor,
  • preclinical studies,
  • anti-cancer agent.
Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code